Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21587611 | 0.81 | TSHR (0.37) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL522950 | 0.81 | TSHR (0.37) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL268203 | 0.81 | TSHR (0.37) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL3114190 | 0.79 | TSHR (0.33) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL3114195 | 0.79 | TSHR (0.33) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL3114193 | 0.79 | TSHR (0.33) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL29020996 | 0.78 | PDE4A (0.32) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL6923351 | 0.78 | TSHR (0.35) | SYKTSHRNR2F2PDE4APDE4B | |
| SCHEMBL2032383 | 0.77 | — | — | |
| SCHEMBL30497399 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491045-B1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | EP | disclosed |
| EP-2491045-B1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | EP | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-8822508-B2 | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA, S.A. (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | UCB PHARMA, S.A. (BE) | 2012-09-27 | — | — | US | disclosed |
| EP-2491045-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB Pharma S.A. (BE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2485314-A1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary cell | Mitsubishi Chemical Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8178246-B2 | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary cell, and carbonate compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2339684-A2 | Nonaqueous electrolytic solution, nonaqueous electrolyte secondary cell, and carbonate compounds | Mitsubishi Chemical Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011047860-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047860-A1 | 2-OXO-1-PYRROLIDINYL IMIDAZOTHIADIAZOLE DERIVATIVES | UCB PHARMA, S.A. (BE) | 2011-04-28 | — | — | WO | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | SYK 2503/4885TSHR 2800/4885NR2F2 2040/4885 |
| US-20120245208-A1 | 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives | CYP3A4, CYP3A43, CYP3A7 | SYK 2758/4885TSHR 3295/4885NR2F2 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.